Back to full list of clinical trials

Ongoing clinical trials for hepatitis C: Actively recruiting


Condition:

HCV/HIV co-infection

Study title:

A5294: A Prospective, Phase III, Open-Label Study of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in HCV/HIV Coinfected Subjects

Description of study:

This study will evaluate the safety, efficacy and tolerability of the drug boceprevir in combination with Peginterferon and Ribavirin for the treatment of HCV in co-infected patients

Basic eligibility criteria:

Adults coinfected with HCV genotype 1 and HIV

Principal Investigator:

Arthur Kim, MD

Contact:

Teri Flynn, RN, MSN, ANP; 617-726-5596


Condition:

Hepatitis C

Study title:

A Phase II Randomized, Double-blind, Placebo Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody against Hepatitis C Virus E2 Glycoprotein (MBL-HCV1) in Hepatitis C Infected Patients Undergoing Liver Transplantation

Description of study:

This is a multicenter study evaluating the effectiveness of a new monoclonal antibody to HCV Genotype 1a in patients undergoing liver transplantation.  Study involves receiving infusion of study drug/placebo pre-op, intra-op and post-op daily for 7 days, followed by a post-op day 14 dose and 8 weeks of follow-up.

Basic eligibility criteria:

Eligible patients will be HCV genotype 1a undergoing cadaveric or living related OLT

Principal Investigator:

Ray Chung, MD

Contact:

Jenna Gustafson; 617-724-3836


Ongoing clinical trials for hepatitis C: No longer recruiting


Study title:

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy with GS-5885 Alone or in Combination with GS-9451 or GS-9256 with Peginterferon Alfa 2a and Ribavirin in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection

Description of study:

This study is providing two investigational drugs in combination with Peginterferon and Ribavirin to adult subjects to evaluate its safety, efficacy and tolerability in treating chronic HCV infection.

Principal Investigator:

Ray Chung, MD


Study title:

A Phase 3, Multicenter, Randomized, Active-Controlled, Study to Investigate Safety and Efficacy of PSI-7977 and Ribavirin for 12 Weeks Compared to Pegylated Interferon and Ribavirin for 24 Weeks in Treatment-Naïve Patients with Chronic Genotype 2 or 3 HCV Infection

Description of study:

This study is evaluating the safety and effectiveness of PSI-7977 + Ribavirin compared to Peginterferon + Ribavirin in adults with HCV genotype 2 or 3.

Principal Investigator:

Ray Chung, MD


Study title:

An Open-Label Study to Explore the Clinical Efficacy of PSI-7977 with Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant

Description of study:

This study is evaluating the effectiveness of PSI-7977 + Ribavirin in treating HCV pre-transplant and preventing HCV recurrence post-transplant.

Principal Investigator:

Ray Chung, MD


Study title:

Open Label Study of Safety and Efficacy with BMS-790052 plus PEG/RBV in Previously Untreated HCV Patients Co-infected with HIV and HCV

Description of study:

This study will evaluate the safety, efficacy and tolerability of the drug BMS-790052 in combination with Peginterferon and Ribavirin for the treatment of HCV in co-infected patients.

Principal Investigator:

Arthur Kim, MD

Back to Top